A Randomized, Double Blind, Placebo-Controlled, Multiple Dose Escalation, Phase 2 Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Efficacy of CM326 in Patients With Moderate-severe Atopic Dermatitis Subjects
Latest Information Update: 07 Feb 2024
At a glance
- Drugs CM 326 (Primary)
- Indications Atopic dermatitis; Eczema
- Focus Adverse reactions
- Sponsors KeyMed Biosciences
Most Recent Events
- 21 Feb 2022 Status changed from not yet recruiting to recruiting.
- 10 Feb 2022 Planned initiation date changed from 1 Jan 2022 to 1 Mar 2022.
- 17 Jan 2022 New trial record